7月17日，诺华发布2025年第二季度业绩。财报显示，第二季度销售净额140.5亿美元，预估140.4亿美元；核心净利润47.1亿美元，预估46.2亿美元；核心每股收益2.42美元，预估2.34美元。
诺华首席执行官Vas Narasimhan在评论2025年第二季度业绩时表示：“诺华本季度再创佳绩，销售额和核心营业收入均实现两位数增长。我们持续推进Kisqali、Pluvicto和Scemblix等新药的上市，展现了我们产品组合的替代潜力。我们还取得了重要的研发线里程碑，包括用于治疗激素敏感性前列腺癌的Pluvicto获得第三个III期临床试验的阳性结果，以及用于治疗脊髓性肌萎缩症（SMA）的OAV101 IT的全球上市申请。我们稳健的资产负债表以及对中长期增长的信心，使我们能够启动高达100亿美元的股票回购计划，这是我们致力于平衡资本配置的一部分。”
财报发布后，诺华美股夜盘拉升，现涨超5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
